# Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

> **NCT02704390** · PHASE3 · COMPLETED · sponsor: **Orient Pharma Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** ORADUR®-Methylphenidate

## Key facts

- **NCT ID:** NCT02704390
- **Lead sponsor:** Orient Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02704390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02704390, "Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02704390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*